Shares of Enzon Pharmaceuticals (ENZN) shot up on the news that Pfizer may be interested in inking a deal with the company. Last year, Enzon sold a manufacturing plant and four marketed products for $300 million in cash to Italy's sigma-tau Group. That left the developer free to focus on its pipeline, which includes metastatic breast cancer drug PEG-SN38. The company recently began Phase II trials of that drug. Its pipeline also includes two Phase I oncology drugs, as well as Oncaspar, which is in Phase I for solid tumors and lymphomas. Neither Enzon nor Pfizer were available to comment on the rumor, according to the Forbes report.
- take a look at this item